United Lab(3933.HK) gets US$9M second milestone from Novo for UBT251

NewTimeSpace News: The United Laboratories International Holdings Limited (3933.HK) said in a voluntary announcement on 24 September that on 23 September 2026, United Biotechnology received a milestone payment of US$9.0 million (after deduction of Danish withholding tax) from Novo for a global Phase II clinical trial of UBT251 Injection of T2DM indication.

The announcement referred to the company's announcement dated 24 March 2025 in relation to the Exclusive License Agreement with Novo Nordisk A/S for UBT251, a triple agonist of the receptors of GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon in clinical study for the treatment of obesity, type 2 diabetes and other diseases.

Under the Exclusive License Agreement and subject to its terms and conditions, United Biotechnology is eligible to receive potential milestone payments of up to US$1.8 billion subject to the achievement of certain development and sales milestones, plus tiered royalties based on annual net sales in the Territory.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.